26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Active as of 2024-04-27

Generated Narrative: Citation

Resource Citation "179621" Version "1" Updated "2023-11-26 22:35:14+0000"

url: https://fevir.net/resources/Citation/179621

identifier: FEvIR Object Identifier/179621, https://pubmed.ncbi.nlm.nih.gov/26028518

version: 1.0.0-ballot

title: 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

status: active

date: 2024-04-27 20:42:39+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')

Medline Base (Citation Artifact Classifier#medline-base)

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2015-09-28

lastReviewDate: 2022-03-30

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()

classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)

currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)

statusDate
activity: PubMed Pubstatus of Received (Citation Status Type#pubmed-pubstatus-received)
period: ?? --> 2015-04-15

statusDate
activity: PubMed Pubstatus of Revised (Citation Status Type#pubmed-pubstatus-revised)
period: ?? --> 2015-05-06

statusDate
activity: PubMed Pubstatus of Accepted (Citation Status Type#pubmed-pubstatus-accepted)
period: ?? --> 2015-05-08

statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2015-06-02 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2015-06-02 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2015-09-29 06:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/26028518, https://doi.org/10.1016/S1470-2045(15)00011-X, pii/S1470-2045(15)00011-X
relatedIdentifier: https://clinicaltrials.gov/NCT00055731
Titles
- Type Language Text
* Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Abstracts
- Text Copyright
* **BACKGROUND:** Early risk-stratified chemotherapy is a standard treatment for breast, colorectal, and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and estramustine improves survival in patients with castration-resistant prostate cancer. We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer. **METHODS:** We did this randomised phase 3 trial at 26 hospitals in France. We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive). All patients underwent a staging pelvic lymph node dissection. Patients were randomly assigned (1:1) to either androgen deprivation therapy (ADT; goserelin 10·8 mg every 3 months for 3 years) plus four cycles of docetaxel on day 2 at a dose of 70 mg/m(2) and estramustine 10 mg/kg per day on days 1-5, every 3 weeks, or ADT only. The randomisation was done centrally by computer, stratified by risk factor. Local treatment was administered at 3 months. Neither patients nor investigators were masked to treatment allocation. The primary endpoint was relapse-free survival in the intention-to-treat population. Follow-up for other endpoints is ongoing. This study is registered with ClinicalTrials.gov, number NCT00055731. **FINDINGS:** We randomly assigned 207 patients to the ADT plus docetaxel and estramustine group and 206 to the ADT only group. Median follow-up was 8·8 years (IQR 8·1-9·7). 88 (43%) of 207 patients in the ADT plus docetaxel and estramustine group had an event (relapse or death) versus 111 (54%) of 206 in the ADT only group. 8-year relapse-free survival was 62% (95% CI 55-69) in the ADT plus docetaxel and estramustine group versus 50% (44-57) in the ADT only group (adjusted hazard ratio [HR] 0·71, 95% CI 0·54-0·94, p=0·017). Of patients who were treated with radiotherapy and had data available, 31 (21%) of 151 in the ADT plus docetaxel and estramustine group versus 26 (18%) of 143 in the ADT only group reported a grade 2 or higher long-term side-effect (p=0·61). We recorded no excess second cancers (26 [13%] of 207 vs 22 [11%] of 206; p=0·57), and there were no treatment-related deaths. **INTERPRETATION:** Docetaxel-based chemotherapy improves relapse-free survival in patients with high-risk localised prostate cancer. Longer follow-up is needed to assess whether this benefit translates into improved metastasis-free survival and overall survival. **FUNDING:** Ligue Contre le Cancer, Sanofi-Aventis, AstraZeneca, Institut National du Cancer. Copyright © 2015 Elsevier Ltd. All rights reserved.
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Lancet Oncol. 2015 Jul;16(7):741-2
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26028517/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/26028517
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Rev Urol. 2015 Jul;12(7):358
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26077993/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/26077993
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Eur Urol. 2015 Dec;68(6):1098-9
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26545569/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/26545569
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Rev Clin Oncol. 2015 Dec;12(12):687-8
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26552950/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/26552950
publicationForm
PublishedIns
- Type Identifier Title PublisherLocation
* Periodical (Published In Type#D020492) Electronic ISSN Type/1474-5488, ISOAbbreviation/Lancet Oncol, ISSN Linking/1470-2045, Medline Title Abbreviation/Lancet Oncol, NLM Unique ID/100957246 The Lancet. Oncology England
citedMedium: Internet (Cited Medium#internet)
volume: 16
issue: 7
articleDate: 2015-07
publicationDateText: 2015-Jul
language: English (Tags for the Identification of Languages#en)
pageString: 787-94
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2015-05-28
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
url: https://pubmed.ncbi.nlm.nih.gov/26028518/
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
url: https://doi.org/10.1016/S1470-2045(15)00011-X
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Taxoids (#D043823), Docetaxel (chemical-substances#15H5577CQD; #D000077143), Estramustine (chemical-substances#35LT29625A; #D004961), Prostate-Specific Antigen (chemical-substances#EC 3.4.21.77; #D017430)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifactAssessment:

artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Dose-Response Relationship, Drug (#D004305)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Administration Schedule (#D004334)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Estramustine (#D004961)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Follow-Up Studies (#D005500)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: France (#D005602)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Kaplan-Meier Estimate (#D053208)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Maximum Tolerated Dose (#D020714)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Invasiveness (#D009361)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Recurrence, Local (#D009364)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: epidemiology (#Q000453)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Staging (#D009367)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Proportional Hazards Models (#D016016)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostate-Specific Antigen (#D017430)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: blood (#Q000097)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Treatment Outcome (#D016896)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Clinical Trial, Phase III (#D017428), Comparative Study (#D003160), Journal Article (#D016428), Multicenter Study (#D016448), Randomized Controlled Trial (#D016449), Research Support, Non-U.S. Gov't (#D013485)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
contributor:

name: Karim Fizazi
forenameInitials: K
affiliation: : Institut Gustave Roussy, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr.
entry
contributor:

name: Laura Faivre
forenameInitials: L
affiliation: : Institut Gustave Roussy, Villejuif, France.
entry
contributor:

name: François Lesaunier
forenameInitials: F
affiliation: : Centre François Baclesse, Caen, France.
entry
contributor:

name: Remy Delva
forenameInitials: R
affiliation: : Institut de Cancérologie de l'Ouest, Angers, France.
entry
contributor:

name: Gwenaëlle Gravis
forenameInitials: G
affiliation: : Institut Paoli Calmettes, Marseille, France.
entry
contributor:

name: Frédéric Rolland
forenameInitials: F
affiliation: : Institut de Cancérologie de l'Ouest, Nantes, France.
entry
contributor:

name: Frank Priou
forenameInitials: F
affiliation: : Centre Hospitalier Départemental, La Roche-sur-Yon, France.
entry
contributor:

name: Jean-Marc Ferrero
forenameInitials: JM
affiliation: : Centre Antoine Lacassagne, Nice, France.
entry
contributor:

name: Nadine Houede
forenameInitials: N
affiliation: : Centre Hospitalier de Nimes, Nimes, France.
entry
contributor:

name: Loïc Mourey
forenameInitials: L
affiliation: : Institut Claudius Regaud, Toulouse, France.
entry
contributor:

name: Christine Theodore
forenameInitials: C
affiliation: : Hôpital Foch, Paris, France.
entry
contributor:

name: Ivan Krakowski
forenameInitials: I
affiliation: : Centre Alexis Vautrin, Nancy, France.
entry
contributor:

name: Jean-François Berdah
forenameInitials: JF
affiliation: : Clinique Sainte-Marguerite, Hyères, France.
entry
contributor:

name: Marjorie Baciuchka
forenameInitials: M
affiliation: : Centre Hospitalier La Timone, Marseille, France.
entry
contributor:

name: Brigitte Laguerre
forenameInitials: B
affiliation: : Centre Eugène Marquis, Rennes, France.
entry
contributor:

name: Aude Fléchon
forenameInitials: A
affiliation: : Centre Léon Bérard, Lyon, France.
entry
contributor:

name: Alain Ravaud
forenameInitials: A
affiliation: : Hôpital Saint-André, Bordeaux, France.
entry
contributor:

name: Isabelle Cojean-Zelek
forenameInitials: I
affiliation: : Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.
entry
contributor:

name: Stéphane Oudard
forenameInitials: S
affiliation: : Hôpital Européen Georges Pompidou, Paris, France.
entry
contributor:

name: Jean-Luc Labourey
forenameInitials: JL
affiliation: : CHU Dupuytren, Limoges, France.
entry
contributor:

name: Paule Chinet-Charrot
forenameInitials: P
affiliation: : Centre Henri Becquerel, Rouen, France.
entry
contributor:

name: Eric Legouffe
forenameInitials: E
affiliation: : Centre Médical Oncogard, Nimes, France.
entry
contributor:

name: Jean-Léon Lagrange
forenameInitials: JL
affiliation: : Hôpital Henri-Mondor, Créteil, France.
entry
contributor:

name: Claude Linassier
forenameInitials: C
affiliation: : Hôpital Bretonneau, Tours, France.
entry
contributor:

name: Gaël Deplanque
forenameInitials: G
affiliation: : Hôpital Saint-Joseph, Paris, France.
entry
contributor:

name: Philippe Beuzeboc
forenameInitials: P
affiliation: : Institut Curie, Paris, France.
entry
contributor:

name: Jean-Louis Davin
forenameInitials: JL
affiliation: : Clinique Sainte-Catherine, Avignon, France.
entry
contributor:

name: Anne-Laure Martin
forenameInitials: AL
affiliation: : Unicancer, Paris, France.
entry
contributor:

name: Muriel Habibian
forenameInitials: M
affiliation: : Unicancer, Paris, France.
entry
contributor:

name: Agnès Laplanche
forenameInitials: A
affiliation: : Institut Gustave Roussy, Villejuif, France.
entry
contributor:

name: Stéphane Culine
forenameInitials: S
affiliation: : Hôpital Saint-Louis, Paris, France.

Generated Narrative: Practitioner #author0
name: Karim Fizazi

Generated Narrative: Practitioner #author1
name: Laura Faivre

Generated Narrative: Practitioner #author2
name: François Lesaunier

Generated Narrative: Practitioner #author3
name: Remy Delva

Generated Narrative: Practitioner #author4
name: Gwenaëlle Gravis

Generated Narrative: Practitioner #author5
name: Frédéric Rolland

Generated Narrative: Practitioner #author6
name: Frank Priou

Generated Narrative: Practitioner #author7
name: Jean-Marc Ferrero

Generated Narrative: Practitioner #author8
name: Nadine Houede

Generated Narrative: Practitioner #author9
name: Loïc Mourey

Generated Narrative: Practitioner #author10
name: Christine Theodore

Generated Narrative: Practitioner #author11
name: Ivan Krakowski

Generated Narrative: Practitioner #author12
name: Jean-François Berdah

Generated Narrative: Practitioner #author13
name: Marjorie Baciuchka

Generated Narrative: Practitioner #author14
name: Brigitte Laguerre

Generated Narrative: Practitioner #author15
name: Aude Fléchon

Generated Narrative: Practitioner #author16
name: Alain Ravaud

Generated Narrative: Practitioner #author17
name: Isabelle Cojean-Zelek

Generated Narrative: Practitioner #author18
name: Stéphane Oudard

Generated Narrative: Practitioner #author19
name: Jean-Luc Labourey

Generated Narrative: Practitioner #author20
name: Paule Chinet-Charrot

Generated Narrative: Practitioner #author21
name: Eric Legouffe

Generated Narrative: Practitioner #author22
name: Jean-Léon Lagrange

Generated Narrative: Practitioner #author23
name: Claude Linassier

Generated Narrative: Practitioner #author24
name: Gaël Deplanque

Generated Narrative: Practitioner #author25
name: Philippe Beuzeboc

Generated Narrative: Practitioner #author26
name: Jean-Louis Davin

Generated Narrative: Practitioner #author27
name: Anne-Laure Martin

Generated Narrative: Practitioner #author28
name: Muriel Habibian

Generated Narrative: Practitioner #author29
name: Agnès Laplanche

Generated Narrative: Practitioner #author30
name: Stéphane Culine

Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Dose-Response Relationship, Drug (#D004305)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Administration Schedule (#D004334)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Estramustine (#D004961)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Follow-Up Studies (#D005500)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: France (#D005602)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Kaplan-Meier Estimate (#D053208)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Maximum Tolerated Dose (#D020714)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Invasiveness (#D009361)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Recurrence, Local (#D009364)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: epidemiology (#Q000453)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neoplasm Staging (#D009367)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Proportional Hazards Models (#D016016)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostate-Specific Antigen (#D017430)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: blood (#Q000097)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Treatment Outcome (#D016896)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()